Ductal Carcinoma In Situ (DCIS)
Ductal carcinoma in situ (DCIS) is a significant challenge in the field of breast cancer management, representing a complex and nuanced condition that has undergone increased scrutiny in recent years. At Alfa Cytology, our team of experienced biologists work with you to develop DCIS therapeutics.
Introduction to Ductal Carcinoma In Situ (DCIS)
DCIS is a non-invasive form of breast cancer, where abnormal cells have been detected within the milk ducts of the breast, but have not yet penetrated the surrounding tissue. With the increased detection capabilities of modern screening techniques, DCIS now accounts for 20-25% of all breast cancer cases.
Fig.1 Progression of ductal carcinoma in situ to invasive breast cancer. (Van Seijen M., et al. 2019)
Therapeutic Development for Ductal Carcinoma In Situ (DCIS)
The primary goal of DCIS treatment is to prevent the development of invasive breast cancer, which can have more severe consequences. Without pr oper intervention, a significant proportion of DCIS lesions will progress to become invasive, increasing the risk of metastatic spread and potentially life-threatening outcomes. By implementing appropriate treatment strategies, such as surgery, radiation therapy, or targeted therapies, healthcare providers can effectively reduce the likelihood of DCIS progression.
| Therapeutics | Types | NCT | Phase |
| Anastrozole | Chemoprevention | NCT00256217 | |
| Pembrolizumab + Intralesional mRNA 2752 | Immunotherapy | NCT02872025 | |
| H2NVAC | Vaccine | NCT04144023 | |
| HER-2 Pulsed Dendritic cell Vaccine | NCT02061332 |
Our Services
At Alfa Cytology, we are committed to advancing the field of DCIS research and translating cutting-edge scientific discoveries into tangible clinical benefits. Our comprehensive suite of services encompasses the full spectrum of preclinical research, from target identification and validation to the evaluation of novel therapeutic strategies.
We provide one-stop solutions for DCIS, including but not limited to the following.
Therapeutics Development
Modeling Services
Preclinical Research
Diagnostic Development
Animal Models of DCIS
Through rigorous research and collaboration with experts in the field, we aim to identify novel therapeutic targets and develop innovative drugs that can effectively treat DCIS while minimizing side effects. Our company's expertise in drug development, including preclinical research and model development, allows us to accelerate pharmaceutical companies' research and development.
|
DCIS Cell Lines |
|
|
HER2-Negative DCIS Cell Lines
HER2-Positive DCIS Cell Lines
|
|
Case Study
A Rat DCIS Intraductal Model for Evaluating Intraductal Nanocarrier Delivery
- Model Introduction
The rat DCIS intraductal model is a critical preclinical tool for studying early-stage breast cancer and evaluating localized therapeutic strategies. The model preserves the ductal anatomy and enables precise evaluation of intraductally administered nanocarriers for localized treatment.
- Model Information
- Model: Rat DCIS Intraductal Model
- Cancer Type: Ductal Carcinoma In Situ (DCIS)
- Host Mouse Strain: Female Fischer 344 Rats
- Age: 6-8 Weeks
- Weight: 150-170 g/li>
- Cell Line Origin: 13762 Mat B III rat mammary adenocarcinoma cells.
- Inoculation Method: Intraductal injection (2.5×105 cells/duct)
- Key Feature: Preserves ductal architecture and enables localized drug delivery evaluation.
- Model Construction
The DCIS model was established by direct intraductal inoculation of 13762 Mat B III cells into the fourth mammary ducts of female Fischer 344 rats. Tumor development was monitored through whole-mount specimens and histopathological analysis at days 2, 3, 6, and 9 post-inoculation, confirming DCIS-like lesion formation and progression to invasive carcinoma.
- In Vivo Efficacy Evaluation
This case utilized the rat DCIS intraductal model to systematically evaluate the anti-tumor efficacy of different formulations administered via intraductal delivery.
- Significant Tumor Growth Inhibition: Intraductal administration of both PEG-A and PEG-A4 nanocarriers effectively suppressed tumor growth compared to untreated controls, with tumor volumes remaining minimal throughout the study period.
- Extended Ductal Retention: PEG-A nanocarriers, including PEG-A and 40 kDa PEG-A4 nanocarriers, showed significantly longer mammary retention half-lives, enabling sustained local drug exposure.
Fig. 2 Retention of compound A and PEG-A nanocarriers in the mammary glands of tumor-bearing rats. Each data point represents the mean ± standard deviation (n = 3). (Source: Alfa Cytology)
We are committed to collaborating with healthcare providers and researchers to drive meaningful progress in this critical area of breast cancer management. By collaborating with Alfa Cytology, clients gain access to a comprehensive suite of services tailored to the unique needs of ductal carcinoma in situ research and therapeutic development. If you are interested in our service, please contact us.
Reference
- Van Seijen M., Lips E. H., and et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. British journal of cancer. 2019, 121(4): 285-292.